These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9205096)

  • 1. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
    Nehyba J; Hrdlicková R; Bose HR
    Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G; Gilmore TD
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
    Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.
    Bhat GV; Temin HM
    Oncogene; 1990 May; 5(5):625-34. PubMed ID: 2189101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
    Carrasco D; Rizzo CA; Dorfman K; Bravo R
    EMBO J; 1996 Jul; 15(14):3640-50. PubMed ID: 8670867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
    Sif S; Capobianco AJ; Gilmore TD
    Oncogene; 1993 Sep; 8(9):2501-9. PubMed ID: 8361761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A yeast transcription assay defines distinct rel and dorsal DNA recognition sequences.
    Kamens J; Brent R
    New Biol; 1991 Oct; 3(10):1005-13. PubMed ID: 1768648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation.
    Zurovec M; Petrenko O; Roll R; Enrietto PJ
    Oncogene; 1998 Jun; 16(24):3133-42. PubMed ID: 9671392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
    Morrison LE; Boehmelt G; Enrietto PJ
    Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
    Fan Y; Gélinas C
    Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. v-rel- and c-rel-protein complexes bind to the NF-kappa B site in vitro.
    Kochel T; Rice NR
    Oncogene; 1992 Mar; 7(3):567-72. PubMed ID: 1549370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of v-rel in a replication competent virus: transformation and biochemical characterization.
    Morrison LE; Boehmelt G; Beug H; Enrietto PJ
    Oncogene; 1991 Sep; 6(9):1657-66. PubMed ID: 1656369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
    Gilmore TD
    Oncogene; 1999 Nov; 18(49):6925-37. PubMed ID: 10602467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two novel functions associated with the Rel oncoproteins: DNA replication and cell-specific transcriptional activation.
    Ishikawa H; Asano M; Kanda T; Kumar S; Gélinas C; Ito Y
    Oncogene; 1993 Nov; 8(11):2889-96. PubMed ID: 8414493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
    Epinat JC; Dvorin EL; Gilmore TD
    Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
    Starczynowski DT; Reynolds JG; Gilmore TD
    Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
    Sarkar S; Gilmore TD
    Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cells.
    Hrdlicková R; Nehyba J; Bose HR
    J Virol; 1995 Jun; 69(6):3369-80. PubMed ID: 7745683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The v-Rel oncoprotein complexes with new Rel- and RelA-related proteins in transformed cells.
    Xu X; Gélinas C
    Virology; 1995 Mar; 207(2):362-8. PubMed ID: 7886940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
    Fan Y; Rayet B; Gélinas C
    Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.